Core Viewpoint - CICC maintains "outperform" rating for CSPC Pharmaceutical Group (01093) and raises target price by 9.1% to HKD 12, while keeping profit forecasts for 2025 and 2026 at CNY 4.76 billion and CNY 5.35 billion, respectively, and introducing a forecast of CNY 5.70 billion for 2027 [1] Group 1 - CSPC Pharmaceutical has signed a research and licensing agreement with AstraZeneca for the exclusive global development, production, and commercialization of eight innovative long-acting peptide drug projects, excluding mainland China and Hong Kong/Macau [2] - AstraZeneca will pay a total of USD 1.2 billion in upfront payments and up to USD 3.5 billion in cumulative milestone payments for development and sales, with Giant Biologics (a subsidiary of New Horizon (300765)) entitled to 35% of the upfront payment and subsequent milestone payments [2] Group 2 - The company is betting on long-acting peptide drugs to compete in the weight loss and metabolic market, with its drug SYH2082 progressing to Phase I clinical trials as a monthly injection GLP1R/GIP agonist [3] - Pfizer's acquisition of Metsera for USD 10 billion highlights the competitive landscape, as Metsera's proprietary NuSH platform enables a long half-life for its weight loss drug MET-097 [3] Group 3 - CSPC has achieved significant external licensing agreements in 2025, including USD 120 million for oral small molecule GLP-1, USD 110 million for the AstraZeneca strategic partnership, and USD 15 million for ROR1ADC, indicating a trend towards regular income from external licensing [4] - The company's R&D pipeline includes advanced innovative assets such as EGFR ADC and SiRNA series, which are expected to lead to further successful licensing and milestone revenue recognition [4]

Core Viewpoint - CICC maintains a "outperform" rating for CSPC Pharmaceutical Group (01093) and raises the target price by 9.1% to HKD 12, considering the continued success of external licensing agreements [1] Group 1: Licensing Agreements and Financial Projections - CSPC has signed a research and licensing agreement with AstraZeneca for the exclusive global development, production, and commercialization of 8 innovative long-acting peptide drug projects, excluding mainland China and Hong Kong/Macau [1] - AstraZeneca will pay a total of USD 1.2 billion in upfront payments and up to USD 3.5 billion in cumulative development and sales milestone payments [1] - The company maintains its profit forecasts for 2025 and 2026 at RMB 4.76 billion and RMB 5.35 billion, respectively, and introduces a forecast of RMB 5.70 billion for 2027 [1] Group 2: Market Position and Competitive Landscape - The company is positioned in the long-acting peptide drug market, competing with major players like Pfizer, which acquired Metsera for USD 10 billion to enhance its weight loss drug portfolio [2] - CSPC's SYH2082 is advancing to Phase I clinical trials as a long-acting GLP1R/GIP agonist, with expectations for favorable efficacy and safety data [2] Group 3: Revenue Generation from Licensing - In 2025, the company has already achieved external licensing revenues from various projects, including USD 120 million from oral small molecule GLP-1 and USD 110 million from the AstraZeneca strategic collaboration [3] - The company has a pipeline of innovative assets, including EGFR ADC and SiRNA series, which are expected to lead to further successful licensing agreements and milestone revenue recognition [3]

Company Updates - The company announced a research and development collaboration and licensing agreement with AstraZeneca for eight innovative long-acting peptide drug projects, including SYH2082 and three preclinical molecules, with an additional four projects under collaboration [1] - AstraZeneca will pay a total of $1.2 billion in upfront payments and up to $3.5 billion in development and sales milestone payments, with a subsidiary entitled to receive 35% of the upfront payment and subsequent milestone payments and royalties [1] Industry Insights - The collaboration marks a significant milestone for Chinese innovative drug licensing abroad, as multinational corporations (MNCs) are betting on long-acting peptide drugs to compete in the weight loss and metabolic market [1] - The company’s SYH2082 is a long-acting GLP1R/GIP agonist progressing to Phase I clinical trials, with expectations for more favorable efficacy and safety data [1] Revenue Generation - The company has achieved external licensing agreements in 2025, including $120 million for oral small molecule GLP-1, $110 million for the AstraZeneca collaboration, and $15 million for other projects, indicating a potential for regular income from licensing [2] - The company has a pipeline of innovative assets, including EGFR ADC/SiRNA series, which are expected to lead to further licensing agreements and milestone revenue recognition [2] Profit Forecast and Valuation - The profit forecast for 2025 and 2026 is maintained at 4.76 billion yuan and 5.35 billion yuan, with an introduction of a 2027 forecast of 5.70 billion yuan [2] - The current stock price corresponds to a price-to-earnings ratio of 18.7 and 17.1 times for 2026 and 2027, respectively, with a target price adjustment of 9.1% to HKD 12.00, implying a 25% upside potential [2]

Group 1 - The U.S. plans to impose a 100% tariff on patented and branded drugs starting October 1, which has led to a significant drop in A-share pharmaceutical stocks, particularly in the CRO and chemical pharmaceutical sectors, with declines exceeding 2% [2] - The proposed tariffs do not apply to raw materials, and it is believed that the tariffs will mainly affect patented drugs, while generic drugs will be exempt [2][3] - Companies such as Huahai Pharmaceutical and Haizheng Pharmaceutical have stated that they will not be affected as they primarily sell generic drugs in the U.S. market [2][3] Group 2 - Kelun Pharmaceutical also confirmed that it would not be impacted by the tariff changes [3] - Currently, among A-share pharmaceutical companies, only BeiGene is independently selling innovative drugs in the U.S. market [4] - BeiGene's stock price fell over 4% on September 26, but company insiders indicated that the tariff policy lacks specific details and should have a limited impact, as their New Jersey facility is in the process of testing and certification [5]

Core Insights - China's innovative drug sector is experiencing explosive growth, with overseas licensing transaction amounts significantly increasing [1] - In the first half of this year, the transaction amount for innovative drug licensing has already exceeded $66 billion, surpassing the total for the entire previous year [1] - The emergence of AI model DeepSeek has drawn global attention, paralleling the advancements in China's biotechnology sector, marking a transition from generic drugs to innovative drugs [1] Industry Developments - Chinese pharmaceutical companies are attracting numerous international collaborations, indicating a shift in the global perception of China's drug innovation capabilities [1] - Notable partnerships include Pfizer's payment of $1.25 billion for the overseas licensing of an innovative drug from 3SBio in May [1] - Major US pharmaceutical companies such as AbbVie, Merck, and Regeneron have signed licensing agreements worth billions with Chinese firms in the first half of this year [1]

Core Insights - In 2024, the company achieved a sales revenue of 138.92 billion yuan from innovative drugs, marking a year-on-year increase of 30.60%, with innovative drug sales accounting for over half of the total sales revenue [1][2] - The company's total operating revenue reached 279.85 billion yuan, a 22.63% increase year-on-year, while net profit attributable to shareholders rose by 47.28% to 63.37 billion yuan [1][2] - The growth in performance is primarily driven by the revenue from innovative drugs, with 19 new molecular entities and 4 other innovative drugs approved for sale in China [1][2] Innovative Drug Development - The company has entered into 13 overseas licensing collaborations for innovative drugs, with 8 of these agreements made in the last three years, contributing to new revenue growth [1][2] - In 2024, the company received significant upfront payments from licensing agreements, including 160 million euros from Merck Healthcare and 100 million USD from Kailera Therapeutics, which positively impacted profits [2] - The company anticipates 47 innovative products to be approved for market, covering various therapeutic areas, with 11 projects expected to launch this year [3] Research and Development Investment - The company reported a record R&D investment of 82.28 billion yuan in 2024, with 65.83 billion yuan classified as expensed R&D, representing 29.40% of total sales revenue [2] - Currently, there are 18 applications for new drug approvals under review by the National Medical Products Administration, with over 90 innovative products in clinical development and approximately 400 clinical trials ongoing [2] Financial Position - As of December 31, 2024, the company had cash and cash equivalents amounting to 248.16 billion yuan, reflecting a year-on-year increase of 19.62% [3]